Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

The podcast explores the biotech industry's resilience amid global uncertainties, focusing on M&A activity and potential impacts of the Middle East conflict. It highlights the sector's strong performance in the first quarter, driven by M&A deals and positive clinical readouts, but notes concerns about prolonged conflict leading to higher oil prices and interest rates, particularly affecting smaller companies. The discussion also covers the potential impact of Vinay Prasad's departure from the FDA on regulatory predictability and Trump's proposed pharma tariffs, which aim to coerce companies into MFN deals, potentially impacting smaller firms reliant on overseas manufacturing. Recent M&A deals by Eli Lilly and Biogen are examined for their strategic implications and potential growth drivers.